Figure 2.
The median overall surviva time of third-line pemetrexed monotherapy (P) in 61 cases was 36.22 months, the median survival time of third-line pemetrexed plus bevacizumab (P + A) in 55 cases was 38.76 months (P=0.04).
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.